{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:05:32Z","timestamp":1784077532383,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) is widely used to assess the risk of preeclampsia. However, heparin can transiently increase the level of circulating sFlt-1, making it unclear whether prophylactic subcutaneous unfractionated heparin (UFH)\u2014commonly used for thromboprophylaxis in pregnancy\u2014affects the reliability of this biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study to compare mid-trimester (18w0d-23w6d) sFlt-1 levels and sFlt-1\/PlGF ratios in 45 pregnant women receiving prophylactic subcutaneous UFH for antiphospholipid syndrome or a history of thrombosis and 563 controls. We also examined the association between biomarker levels and time elapsed since the last UFH injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mid-trimester sFlt-1 levels (1900 vs. 1782 pg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15) and sFlt-1\/PlGF ratios (7.2 vs. 6.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.87) were equivalent between the UFH and control groups. Multivariate regression analysis adjusting for maternal age, body mass index, gestational age at sampling, and low-dose aspirin intake confirmed no significant association between prophylactic UFH and sFlt-1 levels or sFlt-1\/PlGF ratios. Within the UFH group, no correlation was found between the time since administration (range 63\u2013477\u00a0min) and sFlt-1 levels (\n                      <jats:italic>r<\/jats:italic>\n                      =-0.049,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.75) or sFlt-1\/PlGF ratios (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.019,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.90).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prophylactic subcutaneous UFH was not associated with significant differences in sFlt-1\/PlGF ratios, and the serum levels were not correlated with the timing of administration within the examined window. These findings suggest that the sFlt-1\/PlGF ratio may remain a reliable tool for preeclampsia risk assessment in women receiving UFH prophylaxis under routine clinical sampling conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-026-09306-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T03:34:16Z","timestamp":1779420856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of prophylactic subcutaneous unfractionated heparin on the maternal sFlt-1\/PlGF ratio: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yuri","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatake","family":"Toshimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seisuke","family":"Sayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Wada-Hiraike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kumasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"9306_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrneph.2014.102","volume":"10","author":"T Chaiworapongsa","year":"2014","unstructured":"Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466\u201380. https:\/\/doi.org\/10.1038\/nrneph.2014.102.","journal-title":"Nat Rev Nephrol"},{"key":"9306_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1161\/HYPERTENSIONAHA.119.13763","volume":"75","author":"H Stepan","year":"2020","unstructured":"Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome. Hypertension. 2020;75:918\u201326. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13763.","journal-title":"Hypertension"},{"key":"9306_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","volume":"376","author":"EAP Steegers","year":"2010","unstructured":"Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(10)60279-6.","journal-title":"Lancet"},{"key":"9306_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649\u201358. https:\/\/doi.org\/10.1172\/JCI17189.","journal-title":"J Clin Invest"},{"key":"9306_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstr\u00f6m M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1414838.","journal-title":"N Engl J Med"},{"key":"9306_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","volume":"74","author":"X Bian","year":"2019","unstructured":"Bian X, Biswas A, Huang X, Lee KJ, Li TKT, Masuyama H, et al. Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia. Hypertension. 2019;74:164\u201372. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.12760.","journal-title":"Hypertension"},{"key":"9306_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/uog.19178","volume":"53","author":"H Zeisler","year":"2019","unstructured":"Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennstr\u00f6m M, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol. 2019;53:367\u201375. https:\/\/doi.org\/10.1002\/uog.19178.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"9306_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/uog.26032","volume":"61","author":"H Stepan","year":"2023","unstructured":"Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D, et al. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023;61:168\u201380. https:\/\/doi.org\/10.1002\/uog.26032.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"9306_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/ijmm.2023.5292","volume":"52","author":"A Velegrakis","year":"2023","unstructured":"Velegrakis A, Kouvidi E, Fragkiadaki P, Sifakis S. Predictive value of the sFlt-1\/PlGF ratio in women with suspected preeclampsia: An update (Review). Int J Mol Med. 2023;52:89. https:\/\/doi.org\/10.3892\/ijmm.2023.5292.","journal-title":"Int J Mol Med"},{"key":"9306_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jogc.2017.07.014","volume":"40","author":"AM Yusuf","year":"2018","unstructured":"Yusuf AM, Kahane A, Ray JG. First and second trimester serum sFlt-1\/PlGF ratio and subsequent preeclampsia: A systematic review. J Obstet Gynaecol Can. 2018;40:618\u201326. https:\/\/doi.org\/10.1016\/j.jogc.2017.07.014.","journal-title":"J Obstet Gynaecol Can"},{"key":"9306_CR11","doi-asserted-by":"publisher","first-page":"3987453","DOI":"10.1155\/jdr\/3987453","volume":"2025","author":"J Kornacki","year":"2025","unstructured":"Kornacki J, Wender-Ozegowska E, Boro\u0144 D, Mantaj U, Wirstlein P, Gutaj P. sFlt-1\/PlGF ratio in the prediction of preeclampsia in pregnant women with diabetic kidney disease. J Diabetes Res. 2025;2025:3987453. 10.1155\/ jdr \/3987453.","journal-title":"J Diabetes Res"},{"key":"9306_CR12","first-page":"CD012852","volume":"5","author":"EN Hamuly\u00e1k","year":"2020","unstructured":"Hamuly\u00e1k EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020;5:CD012852.","journal-title":"Cochrane Database Syst Rev"},{"key":"9306_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10557-023-07496-3","volume":"39","author":"L Depietri","year":"2023","unstructured":"Depietri L, Veropalumbo MR, Leone MC, Ghirarduzzi A. Antiphospholipid syndrome: state of the art of clinical management. Cardiovasc Drugs Ther. 2023;39:385\u2013404.","journal-title":"Cardiovasc Drugs Ther"},{"key":"9306_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","volume":"295","author":"W Lim","year":"2006","unstructured":"Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050\u20137.","journal-title":"JAMA"},{"key":"9306_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jth.15290","volume":"19","author":"EN Hamuly\u00e1k","year":"2021","unstructured":"Hamuly\u00e1k EN, Scheres LJJ, Goddijn M, Middeldorp S. Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence? J Thromb Haemost. 2021;19:1174\u201385.","journal-title":"J Thromb Haemost"},{"key":"9306_CR16","first-page":"CD001689","volume":"3","author":"P Middleton","year":"2021","unstructured":"Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021;3:CD001689.","journal-title":"Cochrane Database Syst Rev"},{"key":"9306_CR17","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296\u2013304.","journal-title":"Ann Rheum Dis"},{"key":"9306_CR18","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1161\/CIRCULATIONAHA.111.046821","volume":"124","author":"VA Rosenberg","year":"2011","unstructured":"Rosenberg VA, Buhimschi IA, Lockwood CJ, Paidas MJ, Dulay AT, Ramma W, et al. Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy. Circulation. 2011;124:2543\u201353.","journal-title":"Circulation"},{"key":"9306_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCRESAHA.110.239665","volume":"108","author":"S Sela","year":"2011","unstructured":"Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108:1063\u201370.","journal-title":"Circ Res"},{"key":"9306_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1006\/bbrc.1999.1580","volume":"264","author":"M Park","year":"1999","unstructured":"Park M, Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun. 1999;264:730\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"9306_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13293-020-00311-w","volume":"11","author":"KH Moore","year":"2020","unstructured":"Moore KH, Chapman H, George EM. Unfractionated heparin displaces sFlt-1 from the placental extracellular matrix. Biol Sex Differ. 2020;11:34.","journal-title":"Biol Sex Differ"},{"key":"9306_CR22","doi-asserted-by":"publisher","first-page":"e85258","DOI":"10.1371\/journal.pone.0085258","volume":"9","author":"H Hagmann","year":"2014","unstructured":"Hagmann H, Bossung V, Belaidi AA, Fridman A, Karumanchi SA, Thadhani R, et al. Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination. PLoS ONE. 2014;9:e85258.","journal-title":"PLoS ONE"},{"key":"9306_CR23","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1161\/ATVBAHA.111.237784","volume":"31","author":"J Searle","year":"2011","unstructured":"Searle J, Mockel M, Gwosc S, Datwyler SA, Qadri F, Albert GI, et al. Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro\u2013brief report. Arterioscler Thromb Vasc Biol. 2011;31:2972\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9306_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13730-019-00435-y","volume":"9","author":"H Morisawa","year":"2020","unstructured":"Morisawa H, Hirashima C, Sano M, Nagayama S, Takahashi H, Shirasuna K, et al. Difficulty of predicting early-onset super-imposed preeclampsia in pregnant women with hemodialysis due to diabetic nephropathy by serum levels of sFlt-1, PlGF, and sEng. CEN Case Rep. 2020;9:101\u20135.","journal-title":"CEN Case Rep"},{"key":"9306_CR25","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/AOG.0b013e3181deba40","volume":"115","author":"PD Ziakas","year":"2010","unstructured":"Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115:1256\u201362.","journal-title":"Obstet Gynecol"},{"key":"9306_CR26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1213\/ANE.0000000000002530","volume":"126","author":"L Leffert","year":"2018","unstructured":"Leffert L, Butwick A, Carvalho B, Arendt K, Bates SM, Friedman A, et al. The Society for Obstetric Anesthesia and Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants. Anesth Analg. 2018;126:928\u201344.","journal-title":"Anesth Analg"},{"key":"9306_CR27","doi-asserted-by":"crossref","unstructured":"Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6) Suppl:141S-59S.","DOI":"10.1378\/chest.08-0689"},{"key":"9306_CR28","doi-asserted-by":"crossref","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Parenteral anticoagulants: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2) Suppl:e24S-43S.","DOI":"10.1378\/chest.141.5.1369a"},{"key":"9306_CR29","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1345\/aph.1L194","volume":"43","author":"EA Nutescu","year":"2009","unstructured":"Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43:1064\u201383.","journal-title":"Ann Pharmacother"},{"key":"9306_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","volume":"27","author":"LA Magee","year":"2022","unstructured":"Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148\u201369.","journal-title":"Pregnancy Hypertens"},{"key":"9306_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"9306_CR32","doi-asserted-by":"crossref","unstructured":"Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:584\u2009\u2013\u200990. doi: 10.1002\/uog.14817. Epub. PMID: 25678265.","DOI":"10.1002\/uog.14817"},{"key":"9306_CR33","doi-asserted-by":"publisher","unstructured":"Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:591-8. https:\/\/doi.org\/10.1002\/uog.14811. Epub. PMID: 25653039.","DOI":"10.1002\/uog.14811"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-026-09306-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-09306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-09306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:45:15Z","timestamp":1784076315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-026-09306-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9306"],"URL":"https:\/\/doi.org\/10.1186\/s12884-026-09306-8","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective cohort study was conducted at The University of Tokyo Hospital between July 2022 and October 2024 in accordance with the Declaration of Helsinki and with the approval of The University of Tokyo Institutional Review Board (Approval No: 3053-1). Clinical data were obtained from electronic medical records in accordance with the institution\u2019s comprehensive consent policy and the opt-out procedure disclosed on the hospital website,","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"771"}}